Literature DB >> 15613412

Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.

Tae Yong Kim1, Won Bae Kim, Eun Sook Kim, Jin Sook Ryu, Jeong Seok Yeo, Seong Chul Kim, Suck Joon Hong, Young Kee Shong.   

Abstract

We investigated whether serum thyroglobulin (Tg) measured at the time of remnant ablation (ablation-Tg) could be a prognostic indicator complementary to serum Tg levels at the time of the first diagnostic whole-body scan (WBS) after thyroid hormone withdrawal (control-Tg; approximately 6-12 months after ablation-Tg) and whether ablation-Tg could predict the persistence or recurrence of disease in low-risk patients with differentiated thyroid carcinoma. Patients with differentiated thyroid carcinoma (n = 268) treated with total or near-total thyroidectomy followed by immediate (131)I remnant ablation were studied. Patients with anti-Tg autoantibodies and those showing evidence of extracervical metastases were excluded. Two patients showing remnant uptake on follow-up diagnostic WBS received a second ablation. We found significant correlation between ablation-Tg and control-Tg levels; 114 of 143 patients (80%) with ablation-Tg greater than 2 microg/liter showed detectable (>/=1 microg/liter) control-Tg, and 70 of 125 (56%) patients with ablation-Tg 2 microg/liter or less showed undetectable (<1 microg/liter) control-Tg [odds ratio 5.1, 95% confidence interval (CI) 3.0-8.9, P < 0.001]. When the 268 patients were followed up for a mean period of 5.7 +/- 1.4 yr (range 2.8-8.3 yr), 35 (13%) had recurrences; 73 (27%) were classified as "Tg positive, no evidence of disease"; and 160 (60%) showed complete remission. Of 143 patients with ablation-Tg greater than 2 microg/liter, recurrence was observed in 33 cases (23%); "Tg positive, no evidence of disease," was observed in 52 cases (36%); and complete remission was observed in 58 cases (41%). Of 125 patients with ablation-Tg 2 microg/liter or less, two patients (2%) showed recurrence during the follow-up; 21 patients (17%) were regarded as "Tg positive, no evidence of disease"; and 102 patients (81%) showed complete remission. The positive predictive value for recurrence in patients having ablation-Tg greater than 2 microg/liter was found to be 23.1% (33 of 143 patients, 95% CI 16.4-30.8%). The negative predictive value for recurrence in patients having ablation-Tg 2 microg/liter or less was found to be 98.4% (123 of 125 patients, 95% CI 94.4-99.8%). These data indicate that serum Tg levels measured at the time of immediate postoperative (131)I remnant ablation correlated well with serum Tg levels at the time of the initial diagnostic WBS and had a complementary role for predicting persistence or recurrence of disease in the earliest postoperative period.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15613412     DOI: 10.1210/jc.2004-1771

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  58 in total

1.  Postoperative serum thyroglobulin and neck ultrasound to drive decisions about iodine-131 therapy in patients with differentiated thyroid carcinoma: an evidence-based strategy?

Authors:  Luca Giovanella; Anca M Avram; Jerome Clerc; Elif Hindié; David Taïeb; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-30       Impact factor: 9.236

2.  Robotic thyroidectomy by bilateral axillo-breast approach: review of 1,026 cases and surgical completeness.

Authors:  Kyu Eun Lee; Eunyoung Kim; Do Hoon Koo; June Young Choi; Kyu Hyung Kim; Yeo-Kyu Youn
Journal:  Surg Endosc       Date:  2013-02-23       Impact factor: 4.584

3.  Evaluation of the URiSCAN super cassette ACR semiquantitative urine dipstick for microalbuminuria screening.

Authors:  Min-Chul Cho; Misuk Ji; So Young Kim; Wonho Choe; Woochang Lee; Sail Chun; Won-Ki Min
Journal:  J Clin Lab Anal       Date:  2014-02-27       Impact factor: 2.352

4.  Limited clinical value of periablative changes of serum markers in the prediction of biochemical remission in patients with papillary thyroid cancer.

Authors:  Heeyoung Kim; Seong-Jang Kim; In-Joo Kim; Keunyoung Kim; Sojung Kim; Bo Hyun Kim; Sang Soo Kim; Jeon Yoon Kyung
Journal:  Nucl Med Mol Imaging       Date:  2013-08-21

5.  Risk Factors for Re-recurrence After First Reoperative Surgery for Locoregional Recurrent/Persistent Papillary Thyroid Carcinoma.

Authors:  Hwan Seo Lee; Jong-Lyel Roh; Gyungyup Gong; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

6.  Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma.

Authors:  Hee Jeong Park; Geum-Cheol Jeong; Seong Young Kwon; Jung-Joon Min; Hee-Seung Bom; Ki Seong Park; Sang-Geon Cho; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Ari Chong; Su Woong Yoo
Journal:  Nucl Med Mol Imaging       Date:  2014-06-28

Review 7.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

8.  Prognostic Value of the Number of Retrieved Lymph Nodes in Pathological Nx or N0 Classical Papillary Thyroid Carcinoma.

Authors:  Tae-Yon Sung; Jong Ho Yoon; Dong Eun Song; Yu-Mi Lee; Tae-Yong Kim; Ki-Wook Chung; Won Bae Kim; Young Kee Shong; Suck Joon Hong
Journal:  World J Surg       Date:  2016-08       Impact factor: 3.352

9.  Evaluation of whole-body retention of iodine-131 ((131)I) after postoperative remnant ablation for differentiated thyroid carcinoma - thyroxine withdrawal versus rhTSH administration: A retrospective comparison.

Authors:  Maria Raquel Carvalho; Teresa C Ferreira; Valeriano Leite
Journal:  Oncol Lett       Date:  2011-12-14       Impact factor: 2.967

10.  Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.

Authors:  Fabian Pitoia; Erika Abelleira; Graciela Cross
Journal:  Endocrine       Date:  2016-09-21       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.